Cancer Treatment Vaccines
FDA-approved therapeutic vaccines for cancer treatment
This page catalogs 1 therapeutic cancer vaccine product. Unlike preventive vaccines, therapeutic vaccines are designed to treat existing disease by stimulating an immune response against cancer cells. Provenge (sipuleucel-T) was the first FDA-approved cancer treatment vaccine, using the patient's own dendritic cells to target prostate cancer. HPV vaccines, which prevent cancer by preventing infection, are cataloged separately on the HPV Vaccines page.
Last updated: April 2026.
Cancer Treatment Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Provenge | Sipuleucel-T (autologous cellular immunotherapy) | Dendreon | Autologous dendritic cell | FDA Licensed, 2010 | First FDA-approved cancer treatment vaccine; prostate cancer |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026). Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.